ABT · CIK 1800
What Abbott Laboratories told the SEC could break it.
Abbott's disclosures point first to geography: emerging markets are 37% of total company sales, concentrating both growth and risk in less-stable economies, with its Diagnostics segment specifically hampered by challenging conditions in China. On the supply side, it uses third-party manufacturers and single suppliers for certain products and materials, so a production problem — from raw materials, a failed batch, a cyber event or a disaster — could force discards, recalls and product-liability costs. Overlaying both is comprehensive FDA and international regulation of how its products are developed, approved, manufactured and marketed.
3 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Geographic concentration
- emerging markets 37% of sales; China diagnostics weaknessmedium
Emerging markets represent 37% of Abbott's total company sales, and its Diagnostic Products segment continued to be impacted by challenging market conditions in China — concentrating growth and risk in less-stable geographies.
“Sales in emerging markets, which represent 37 percent of total company sales, increased 5.1 percent in 2025 and 8.2 percent in 2024, excluding the impact of foreign exchange.”
Sole-source dependency
- third-party manufacturers and single suppliers for certain products and materialsmedium
Abbott uses third-party manufacturers and single suppliers for certain products and materials; production problems (raw materials, supply chain, spec failures, cyber, disasters) could force product discard, recalls, and product-liability costs.
“third-party manufacturers and single suppliers are currently used for certain products and materials. If problems arise during the production of a lot or batch of product, those products may have to be discarded.”
SEC filing →As of 2026
Regulatory & policy
- comprehensive FDA and international regulation of product development/marketinglow
The development, manufacture, marketing, sale and distribution of Abbott's products are subject to comprehensive government regulation by the FDA and similar national/international agencies, spanning development and market approval.
“The development, manufacture, marketing, sale, promotion, and distribution of Abbott's products are subject to comprehensive government regulation by the U.S. Food and Drug Administration (FDA) and similar national and international regulatory agencies.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
“During 2025, three of our customers, Abbott Laboratories, Boston Scientific and Medtronic were each in excess of 10% of total sales and collectively accounted for 49% of our total sales.”
Cited →“Significant Customers OTHER FACTORS IMPACTING OUR OPERATIONS Revenue from Abbott and Medtronic represented approximately 16% and 12%, respectively, of our consolidated revenue for fiscal 2024.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch